A retrospective study of comparative effectiveness of sacubitril/valsartan versus angiotensin converting enzyme inhibitors/angiotensin receptor blockers in de novo heart failure patients
Latest Information Update: 13 Oct 2022
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
Most Recent Events
- 13 Oct 2022 New trial record
- 29 Aug 2022 Results presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology